Ali Raza Khaki1,2,3, Shasank Chennupati4, Catherine Fedorenko4, Li Li4, Qin Sun4, Petros Grivas1,2, Scott D Ramsey1,4, Stephen M Schwartz5, Veena Shankaran1,4. 1. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA. 4. Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research, Seattle, WA. 5. Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract
PURPOSE: Systemic therapy use in the last 30 days of life (DOL) for patients with advanced cancer is a low-value medical practice. We hypothesized that systemic therapy use in the last 30 DOL increased after approval of antiprogrammed cell death protein 1 immune checkpoint inhibitors (ICIs) and has contributed to increased health care utilization and spending. METHODS: We investigated the change in prevalence of any systemic therapy use in the last 30 DOL among patients with advanced solid tumors in the 4 years before and after antiprogrammed cell death protein 1 ICI approval in 2014. We used cases from the Western Washington Cancer Surveillance System linked to commercial and Medicare insurance. We calculated the difference in prevalence between the pre- and post-ICI periods. We also calculated the annual prevalence of any systemic therapy and ICI use in the last 30 DOL and measured health care utilization (emergency department visits and hospitalizations) and costs during the last 30 DOL. RESULTS: Eight thousand eight hundred seventy-one patients (median age 73 years) were included; 34% and 66% in the pre-and post-ICI period, respectively. Systemic therapy use in the last 30 DOL was lower in the post-ICI versus pre-ICI period (12.4% v 14.4%; difference -2.0% [95% CI, -3.5 to -0.5]). The annual prevalence of systemic therapy use in the last 30 DOL also declined, although ICI use rose. Patients treated with ICIs in last 30 DOL had more emergency department visits, hospitalizations, and higher costs. CONCLUSION: Systemic therapy use in the last 30 DOL was lower in the period after ICI approval. However, ICI use rose over time and had higher utilization and costs in the last 30 DOL. Systemic therapy use in the last 30 DOL warrants monitoring, especially as more ICI indications are approved.
PURPOSE: Systemic therapy use in the last 30 days of life (DOL) for patients with advanced cancer is a low-value medical practice. We hypothesized that systemic therapy use in the last 30 DOL increased after approval of antiprogrammed cell death protein 1 immune checkpoint inhibitors (ICIs) and has contributed to increased health care utilization and spending. METHODS: We investigated the change in prevalence of any systemic therapy use in the last 30 DOL among patients with advanced solid tumors in the 4 years before and after antiprogrammed cell death protein 1 ICI approval in 2014. We used cases from the Western Washington Cancer Surveillance System linked to commercial and Medicare insurance. We calculated the difference in prevalence between the pre- and post-ICI periods. We also calculated the annual prevalence of any systemic therapy and ICI use in the last 30 DOL and measured health care utilization (emergency department visits and hospitalizations) and costs during the last 30 DOL. RESULTS: Eight thousand eight hundred seventy-one patients (median age 73 years) were included; 34% and 66% in the pre-and post-ICI period, respectively. Systemic therapy use in the last 30 DOL was lower in the post-ICI versus pre-ICI period (12.4% v 14.4%; difference -2.0% [95% CI, -3.5 to -0.5]). The annual prevalence of systemic therapy use in the last 30 DOL also declined, although ICI use rose. Patients treated with ICIs in last 30 DOL had more emergency department visits, hospitalizations, and higher costs. CONCLUSION: Systemic therapy use in the last 30 DOL was lower in the period after ICI approval. However, ICI use rose over time and had higher utilization and costs in the last 30 DOL. Systemic therapy use in the last 30 DOL warrants monitoring, especially as more ICI indications are approved.
Authors: Andrew J Cohen; Hartley Brody; German Patino; Medina Ndoye; Aron Liaw; Christi Butler; Benjamin N Breyer Journal: JAMA Intern Med Date: 2019-12-01 Impact factor: 21.873
Authors: Holly G Prigerson; Yuhua Bao; Manish A Shah; M Elizabeth Paulk; Thomas W LeBlanc; Bryan J Schneider; Melissa M Garrido; M Carrington Reid; David A Berlin; Kerin B Adelson; Alfred I Neugut; Paul K Maciejewski Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: Laura A Petrillo; Areej El-Jawahri; Ryan D Nipp; Morgan R L Lichtenstein; Sienna M Durbin; Kerry L Reynolds; Joseph A Greer; Jennifer S Temel; Justin F Gainor Journal: Cancer Date: 2020-03-06 Impact factor: 6.860
Authors: Ravi B Parikh; Matthew D Galsky; Bishal Gyawali; Fauzia Riaz; Tara L Kaufmann; Aaron B Cohen; Blythe J S Adamson; Cary P Gross; Neal J Meropol; Ronac Mamtani Journal: Oncologist Date: 2019-04-03
Authors: Ali Raza Khaki; Ang Li; Leonidas N Diamantopoulos; Mehmet A Bilen; Victor Santos; John Esther; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Hussein Assi; Benjamin A Gartrell; Alex Sankin; Alejo Rodriguez-Vida; Mark Lythgoe; David J Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Praneeth Baratam; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Veena Shankaran; Gary H Lyman; Petros Grivas Journal: Cancer Date: 2019-12-12 Impact factor: 6.921